tiprankstipranks
Trending News
More News >
NewAmsterdam Pharma Company (NAMS)
NASDAQ:NAMS
US Market

NewAmsterdam Pharma Company (NAMS) Stock Forecast & Price Target

Compare
174 Followers
See the Price Targets and Ratings of:

NAMS Analyst Ratings

Strong Buy
9Ratings
Strong Buy
9 Buy
0 Hold
0 Sell
Based on 9 analysts giving stock ratings to
NewAmsterdam
Pharma Company
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

NAMS Stock 12 Month Forecast

Average Price Target

$42.57
▲(118.20%Upside)
Based on 9 Wall Street analysts offering 12 month price targets for NewAmsterdam Pharma Company in the last 3 months. The average price target is $42.57 with a high forecast of $52.00 and a low forecast of $37.00. The average price target represents a 118.20% change from the last price of $19.51.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"15":"$15","34":"$34","53":"$53","24.5":"$24.5","43.5":"$43.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":52,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$52.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":42.57,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$42.57</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":37,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$37.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[15,24.5,34,43.5,53],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2024","6":"Dec<br/>2024","9":"Mar<br/>2025","12":"Jun<br/>2025","25":"Jun<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,18.93,21.473846153846154,24.017692307692307,26.56153846153846,29.105384615384615,31.64923076923077,34.19307692307692,36.73692307692308,39.28076923076923,41.824615384615385,44.36846153846154,46.91230769230769,49.456153846153846,{"y":52,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,18.93,20.748461538461537,22.566923076923075,24.385384615384616,26.203846153846154,28.02230769230769,29.840769230769233,31.65923076923077,33.47769230769231,35.29615384615384,37.114615384615384,38.933076923076925,40.75153846153846,{"y":42.57,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,18.93,20.32,21.71,23.1,24.490000000000002,25.880000000000003,27.27,28.66,30.05,31.44,32.83,34.22,35.61,{"y":37,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":18.75,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.58,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.26,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.42,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.29,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.82,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.64,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.7,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.29,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.38,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.03,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.93,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$52.00Average Price Target$42.57Lowest Price Target$37.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TipRanks Analyst forecast on NAMS
TipRanks AITipRanks
Not Ranked
TipRanks
$19.5
Hold
-0.05%
Downside
Reiterated
06/03/25
The overall stock score of 56 reflects mixed financial performance with growth potential overshadowed by current profitability challenges. Technical analysis shows a neutral trend, while the valuation remains strained due to lack of profitability. Positive corporate events, including promising trial results and strategic board appointments, are significant factors supporting the score.
Cantor Fitzgerald Analyst forecast on NAMS
Steven SeedhouseCantor Fitzgerald
Cantor Fitzgerald
$42
Buy
115.27%
Upside
Initiated
06/04/25
NewAmsterdam Pharma initiated with an Overweight at Cantor FitzgeraldNewAmsterdam Pharma initiated with an Overweight at Cantor Fitzgerald
William Blair Analyst forecast on NAMS
Matt PhippsWilliam Blair
William Blair
Buy
Reiterated
06/04/25
Buy Rating Affirmed for NewAmsterdam Pharma: Obicetrapib's Promising Clinical Profile and Market Potential Highlighted
RBC Capital Analyst forecast on NAMS
Leonid TimashevRBC Capital
RBC Capital
$38
Buy
94.77%
Upside
Reiterated
06/03/25
NewAmsterdam Pharma Company (NAMS) Receives a Buy from RBC Capital
Jefferies Analyst forecast on NAMS
Dennis DingJefferies
Jefferies
$45
Buy
130.65%
Upside
Reiterated
06/02/25
Strong Investment Potential for NewAmsterdam Pharma's Obicetrapib Due to Cardiovascular and Metabolic Benefits
Leerink Partners Analyst forecast on NAMS
Roanna RuizLeerink Partners
Leerink Partners
$44
Buy
125.53%
Upside
Reiterated
05/22/25
Buy Rating for NewAmsterdam Pharma: Obicetrapib's Potential in Cardiovascular Risk Reduction and Revenue Growth
Scotiabank Analyst forecast on NAMS
George FarmerScotiabank
Scotiabank
$52
Buy
166.53%
Upside
Reiterated
05/09/25
Wall Street Analysts Are Bullish on Top Healthcare Picks
Needham
$42$40
Buy
105.02%
Upside
Reiterated
05/08/25
Buy Rating Affirmed for NewAmsterdam Pharma: Strategic Progress and Financial Stability Drive Confidence
TD Cowen
Buy
Reiterated
05/08/25
NewAmsterdam Pharma's Promising Phase III Results and Strategic Plans Garner Buy Rating
Piper Sandler Analyst forecast on NAMS
Yasmeen RahimiPiper Sandler
Piper Sandler
$37
Buy
89.65%
Upside
Reiterated
04/01/25
Piper Sandler Sticks to Their Buy Rating for NewAmsterdam Pharma Company (NAMS)
Guggenheim
$35$41
Buy
110.15%
Upside
Reiterated
03/03/25
NewAmsterdam Pharma price target raised to $41 from $35 at GuggenheimNewAmsterdam Pharma price target raised to $41 from $35 at Guggenheim
H.C. Wainwright Analyst forecast on NAMS
Ed ArceH.C. Wainwright
H.C. Wainwright
$48
Buy
146.03%
Upside
Reiterated
01/14/25
Promising Outlook for NewAmsterdam Pharma: Ed Arce's Buy Rating Backed by Strategic Developments and Phase 3 SuccessesWe employ a risk-adjusted NPV (rNPV) valuation model to estimate the value of NAMS shares, and arrive at our $48 PT based on: (1) about $29 per share for U.S. net sales and EU royalties on obicetrapib in secondary ASCVD prevention (assume commercial launch in 1H27; 85% PoS; $4.7B global peak revenues in 2042); and (2) about $19 per share as a placeholder value for obicetrapib in primary ASCVD prevention (about 40% larger opportunity than secondary prevention; 40% PoS). In our valuation model, we employ a 12.0% discount rate, which we believe adequately reflects the overall risks facing NewAmsterdam.
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TipRanks Analyst forecast on NAMS
TipRanks AITipRanks
Not Ranked
TipRanks
$19.5
Hold
-0.05%
Downside
Reiterated
06/03/25
The overall stock score of 56 reflects mixed financial performance with growth potential overshadowed by current profitability challenges. Technical analysis shows a neutral trend, while the valuation remains strained due to lack of profitability. Positive corporate events, including promising trial results and strategic board appointments, are significant factors supporting the score.
Cantor Fitzgerald Analyst forecast on NAMS
Steven SeedhouseCantor Fitzgerald
Cantor Fitzgerald
$42
Buy
115.27%
Upside
Initiated
06/04/25
NewAmsterdam Pharma initiated with an Overweight at Cantor FitzgeraldNewAmsterdam Pharma initiated with an Overweight at Cantor Fitzgerald
William Blair Analyst forecast on NAMS
Matt PhippsWilliam Blair
William Blair
Buy
Reiterated
06/04/25
Buy Rating Affirmed for NewAmsterdam Pharma: Obicetrapib's Promising Clinical Profile and Market Potential Highlighted
RBC Capital Analyst forecast on NAMS
Leonid TimashevRBC Capital
RBC Capital
$38
Buy
94.77%
Upside
Reiterated
06/03/25
NewAmsterdam Pharma Company (NAMS) Receives a Buy from RBC Capital
Jefferies Analyst forecast on NAMS
Dennis DingJefferies
Jefferies
$45
Buy
130.65%
Upside
Reiterated
06/02/25
Strong Investment Potential for NewAmsterdam Pharma's Obicetrapib Due to Cardiovascular and Metabolic Benefits
Leerink Partners Analyst forecast on NAMS
Roanna RuizLeerink Partners
Leerink Partners
$44
Buy
125.53%
Upside
Reiterated
05/22/25
Buy Rating for NewAmsterdam Pharma: Obicetrapib's Potential in Cardiovascular Risk Reduction and Revenue Growth
Scotiabank Analyst forecast on NAMS
George FarmerScotiabank
Scotiabank
$52
Buy
166.53%
Upside
Reiterated
05/09/25
Wall Street Analysts Are Bullish on Top Healthcare Picks
Needham
$42$40
Buy
105.02%
Upside
Reiterated
05/08/25
Buy Rating Affirmed for NewAmsterdam Pharma: Strategic Progress and Financial Stability Drive Confidence
TD Cowen
Buy
Reiterated
05/08/25
NewAmsterdam Pharma's Promising Phase III Results and Strategic Plans Garner Buy Rating
Piper Sandler Analyst forecast on NAMS
Yasmeen RahimiPiper Sandler
Piper Sandler
$37
Buy
89.65%
Upside
Reiterated
04/01/25
Piper Sandler Sticks to Their Buy Rating for NewAmsterdam Pharma Company (NAMS)
Guggenheim
$35$41
Buy
110.15%
Upside
Reiterated
03/03/25
NewAmsterdam Pharma price target raised to $41 from $35 at GuggenheimNewAmsterdam Pharma price target raised to $41 from $35 at Guggenheim
H.C. Wainwright Analyst forecast on NAMS
Ed ArceH.C. Wainwright
H.C. Wainwright
$48
Buy
146.03%
Upside
Reiterated
01/14/25
Promising Outlook for NewAmsterdam Pharma: Ed Arce's Buy Rating Backed by Strategic Developments and Phase 3 SuccessesWe employ a risk-adjusted NPV (rNPV) valuation model to estimate the value of NAMS shares, and arrive at our $48 PT based on: (1) about $29 per share for U.S. net sales and EU royalties on obicetrapib in secondary ASCVD prevention (assume commercial launch in 1H27; 85% PoS; $4.7B global peak revenues in 2042); and (2) about $19 per share as a placeholder value for obicetrapib in primary ASCVD prevention (about 40% larger opportunity than secondary prevention; 40% PoS). In our valuation model, we employ a 12.0% discount rate, which we believe adequately reflects the overall risks facing NewAmsterdam.
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering NewAmsterdam Pharma Company

1 Month
xxx
Success Rate
5/8 ratings generated profit
63%
Average Return
+1.55%
reiterated a xxx
rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 62.50% of your transactions generating a profit, with an average return of +1.55% per trade.
3 Months
xxx
Success Rate
5/8 ratings generated profit
63%
Average Return
+6.20%
reiterated a xxx
rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 62.50% of your transactions generating a profit, with an average return of +6.20% per trade.
1 Year
Roanna RuizLeerink Partners
Success Rate
9/18 ratings generated profit
50%
Average Return
+24.42%
reiterated a buy rating 16 days ago
Copying Roanna Ruiz's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +24.42% per trade.
2 Years
xxx
Success Rate
10/18 ratings generated profit
56%
Average Return
+25.86%
reiterated a xxx
rating 16 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 55.56% of your transactions generating a profit, with an average return of +25.86% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

NAMS Analyst Recommendation Trends

Rating
Feb 25
Mar 25
Apr 25
May 25
Jun 25
Strong Buy
14
9
9
11
12
Buy
4
4
4
4
5
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
18
13
13
15
17
In the current month, NAMS has received 17 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. NAMS average Analyst price target in the past 3 months is 42.57.
Each month's total comprises the sum of three months' worth of ratings.

NAMS Financial Forecast

NAMS Earnings Forecast

Next quarter’s earnings estimate for NAMS is -$0.49 with a range of -$0.55 to -$0.42. The previous quarter’s EPS was -$0.35. NAMS beat its EPS estimate 75.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.04% of the time in the same period. In the last calendar year NAMS has Outperformed its overall industry.
Next quarter’s earnings estimate for NAMS is -$0.49 with a range of -$0.55 to -$0.42. The previous quarter’s EPS was -$0.35. NAMS beat its EPS estimate 75.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.04% of the time in the same period. In the last calendar year NAMS has Outperformed its overall industry.

NAMS Sales Forecast

Next quarter’s sales forecast for NAMS is $1.62M with a range of $0.00 to $5.80M. The previous quarter’s sales results were $2.98M. NAMS beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 47.51% of the time in the same period. In the last calendar year NAMS has Outperformed its overall industry.
Next quarter’s sales forecast for NAMS is $1.62M with a range of $0.00 to $5.80M. The previous quarter’s sales results were $2.98M. NAMS beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 47.51% of the time in the same period. In the last calendar year NAMS has Outperformed its overall industry.

NAMS Stock Forecast FAQ

What is NAMS’s average 12-month price target, according to analysts?
Based on analyst ratings, NewAmsterdam Pharma Company’s 12-month average price target is 42.57.
    What is NAMS’s upside potential, based on the analysts’ average price target?
    NewAmsterdam Pharma Company has 118.20% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is NAMS a Buy, Sell or Hold?
          NewAmsterdam Pharma Company has a consensus rating of Strong Buy which is based on 9 buy ratings, 0 hold ratings and 0 sell ratings.
            What is NewAmsterdam Pharma Company’s price target?
            The average price target for NewAmsterdam Pharma Company is 42.57. This is based on 9 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $52.00 ,the lowest forecast is $37.00. The average price target represents 118.20% Increase from the current price of $19.51.
              What do analysts say about NewAmsterdam Pharma Company?
              NewAmsterdam Pharma Company’s analyst rating consensus is a Strong Buy. This is based on the ratings of 9 Wall Streets Analysts.
                How can I buy shares of NAMS?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis